NeoPharm Co Ltd
KOSDAQ:092730
Intrinsic Value
NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. [ Read More ]
The intrinsic value of one NeoPharm Co Ltd stock under the Base Case scenario is 25 090.58 KRW. Compared to the current market price of 24 750 KRW, NeoPharm Co Ltd is Undervalued by 1%.
Valuation Backtest
NeoPharm Co Ltd
Run backtest to discover the historical profit from buying and selling NeoPharm Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
NeoPharm Co Ltd
Current Assets | 134.5B |
Cash & Short-Term Investments | 112B |
Receivables | 10.4B |
Other Current Assets | 12.1B |
Non-Current Assets | 43B |
Long-Term Investments | 10.3B |
PP&E | 29.2B |
Intangibles | 2.2B |
Other Non-Current Assets | 1.2B |
Current Liabilities | 16.9B |
Accounts Payable | 6.4B |
Other Current Liabilities | 10.5B |
Non-Current Liabilities | 487.8m |
Long-Term Debt | 430m |
Other Non-Current Liabilities | 57.7m |
Earnings Waterfall
NeoPharm Co Ltd
Revenue
|
97.1B
KRW
|
Cost of Revenue
|
-31.7B
KRW
|
Gross Profit
|
65.4B
KRW
|
Operating Expenses
|
-40.1B
KRW
|
Operating Income
|
25.3B
KRW
|
Other Expenses
|
-2.1B
KRW
|
Net Income
|
23.2B
KRW
|
Free Cash Flow Analysis
NeoPharm Co Ltd
Profitability Score
Profitability Due Diligence
NeoPharm Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
NeoPharm Co Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
NeoPharm Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
NeoPharm Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
NeoPharm Co Ltd
According to Wall Street analysts, the average 1-year price target for NeoPharm Co Ltd is 36 000 KRW .
Shareholder Return
Price
NeoPharm Co Ltd
Average Annual Return | -19.23% |
Standard Deviation of Annual Returns | 13.86% |
Max Drawdown | -70% |
Market Capitalization | 193.6B KRW |
Shares Outstanding | 7 820 627 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeoPharm Co., Ltd. engages in the development, manufacture, and sale of cosmetics, medical, and health products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2007-01-30. The firm produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. The company also engages in the original equipment manufacturing (OEM) of skin drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one NeoPharm Co Ltd stock under the Base Case scenario is 25 090.58 KRW.
Compared to the current market price of 24 750 KRW, NeoPharm Co Ltd is Undervalued by 1%.